Schrödinger, Inc. 10-Qquarter ended 2026-09-30

Executive Summary

Schrödinger sells molecular-design software to biopharma and materials-science researchers and earns research and milestone payments from drug-discovery partnerships. It is shifting customers toward hosted software and AI tools while reducing independent clinical development and seeking partners for its drug candidates. Q3 revenue grew 19% vs 8% for 9M, but milestone income drove much of the improvement while software’s transition continued to obscure underlying demand. Lower development spending narrowed operating losses; investors must distinguish repeatable software growth from unpredictable collaboration payments and investment gains.

What's Happening in the Business

Hosted software is replacing upfront license sales with revenue recognized over contract terms. Q3 hosted revenue rose 49% to $17.2M, while on-premise revenue fell 16% to $13.4M and maintenance fell 33% to $4.57M. Software annual contract value, a contract-performance measure rather than a revenue forecast, grew 17% to $44.7M, suggesting stronger contracting than reported software revenue alone shows.

Schrödinger launched early access to Bunsen, its agentic AI co-scientist, in July. Management expects full commercial release by year-end, and a September Bristol Myers Squibb agreement supports deployment and additional functionality.

Drug discovery is becoming more partner-dependent. Schrödinger plans to finish Phase 1 trials of SGR-1505 and SGR-3515, then seek partners rather than independently start further trials. This retreat from independent clinical development, together with the prior restructuring, is expected to save ≈$70M when completed. August’s licensing of two early-stage programs to newly formed Tectora for equity and potential future payments follows that direction.

Partner decisions remain consequential: September’s Novartis amendment replaced research programs with two new programs, while Bristol Myers Squibb discontinuations left one active neurology target. Novartis’s $150M upfront payment was received in January 2025—not this quarter—and potential future milestones remain contingent.

Key Financial Highlights

• Drug-discovery drivers: A $12.0M Structure Therapeutics milestone supported Q3 growth. The 9M period also included a $10.0M Ajax milestone and accelerated revenue recognition after Lilly discontinued a program and Schrödinger completed its obligations.
• Software economics: Products-and-services revenue grew 6.2% in Q3 but fell 9.1% over 9M. Its Q3 gross margin fell to 75% from 77%, reflecting higher cloud-computing and personnel costs.
• Shared expenses: Segment gross profit excludes operating expenses. Q3 R&D fell 20% to $34.1M; external preclinical and clinical costs fell 54% to $6.96M following SGR-2921’s discontinuation and reduced program spending.
• Investment volatility: Q3 equity revaluation produced a $14.8M loss vs a $9.69M gain, principally reflecting Structure Therapeutics’ share price rather than operating performance.
• Cash and commitments: Liquidity totaled $373M, with management projecting at least 24 months of funding. Cash use included a $43.5M deferred-revenue reduction, while equity-investment sales supplied $67.5M outside operations. An $82.0M three-year cloud minimum and $150M of lease payments through 2037 constrain flexibility.
• Revenue visibility: Remaining performance obligations fell 22% since year-end to $187M; ≈62% is expected within 12 months. These are future revenue, not cash or profit.

Risk Assessment

• Partner and customer dependence: Two customers generated 35% of Q3 revenue, while partner-controlled program cancellations can remove future milestones and royalties.
• Software transition and competition: Hosted migration delays recognition, while nonbinding renewals, competing AI tools and customer-built software threaten contract growth and pricing.
• Clinical uncertainty: Both retained clinical programs remain in Phase 1; SGR-2921’s discontinuation after two patient deaths illustrates the safety risk that could prevent partnering.
• Funding and investment exposure: Persistent cash consumption and fixed commitments could eventually require dilutive financing, while collaborator equity holdings can lose value independently of software performance.

What to Watch

• Hosted migration: Contract value is growing faster than software revenue; sustained contract growth followed by revenue growth would validate the transition, while weaker renewals would challenge it.
• Bunsen commercialization: Management targets year-end release; subsequent customer deployments and software growth would support adoption, while delays or limited uptake would weaken the case.
• Partnership execution: Watch Phase 1 progress, licensing of the retained clinical candidates and advancement of the replacement Novartis programs; new agreements and milestones would validate the partner-led model.
• Cash discipline: Lower clinical spending must translate into reduced cash consumption without weakening software development; continued heavy outflows would shorten the stated funding horizon.